Indication
Non-small cell lung cancer – advanced or metastatic, with EGFR mutations
Dose
Non-small cell lung cancer – advanced or metastatic, with EGFR mutations
- Oral: 240 mg once daily continuously until disease progression or unacceptable toxicity
- Given in combination with amivantamab
Supplied
Available as 80 mg and 240 mg film-coated tablets. Tablets should NOT be crushed or broken. Store at room temperature.
Pharmacological Category
EGFR (epidermal growth factor receptor) inhibitor
Administration
Take with or without food
Missed Dose
If a dose is missed, patients should be instructed to take it as soon as they can if it is within 12 hours of the missed dose. If it is over 12 hours since the missed dose, patients should skip the missed dose and resume with the next scheduled dose.
Adverse Effects
Common: Edema, Venous thromboembolism, Constipation, Fatigue, Dry skin, Rash, Nail disease, Stomatitis, Arthralgia, Electrolyte imbalances.
Less Common: Nausea, Vomiting, Diarrhea, Neuropathy, Eye disorders including conjunctivitis and keratitis, Cardiac injury, Left ventricular ejection fraction decrease, Interstitial lung disease, Pneumonitis.
The adverse effects listed above are not exhaustive. Please refer to the relevant product monograph for full details.
Monitoring Parameters
Baseline before treatment: CBC & differential, platelets, creatinine, alkaline phosphatase, AST, ALT, total bilirubin, calcium, potassium, magnesium.
During treatment: CBC & differential, platelets, creatinine, alkaline phosphatase, AST, ALT, total bilirubin, potassium, calcium and magnesium.
If clinically indicated: ECG.
Drug Interactions
- This drug can impact or be impacted by metabolic enzymes for absorption and excretion. Many drugs can also affect or be affected by these enzymes, so please consult with pharmacy to assess for interactions.
- Current drug interaction databases should be consulted for more information.
Clinical Pearls
- Avoid in pregnancy and lactation.
- Serious and fatal deep vein thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism, have been reported in patients using lazertinib in combination with amivantamab. Prophylactic anticoagulation is recommended for the first 4 months of treatment, and patients should be monitored for signs and symptoms of VTE events and treat as medically appropriate.
- Ocular events have been reported. Contact lens use is a risk factor for ocular toxicity, including keratitis. Caution should be used when driving or operating machinery in patients who experience visual disturbances.
- Monitor for ILD (interstitial lung disease), which can be fatal.
References
Lexicomp. Lazertinib Monograph. In: Lexi-Drugs. Hudson, Ohio: Lexi-Comp, Inc.; 2023]. Accessed November 14th, 2025.
Janssen. Lazcluze Product Monograph. In: Health Canada, Drug Product Database. Available at: /https://pdf.hres.ca/dpd_pm/00078792.PDF Updated March 6th, 2025. Accessed November 14th, 2025.
